ライフサイエンスコーパス: lansoprazole

1 esomeprazole but not with dexlansoprazole or lansoprazole.

2 All patients received lansoprazole.

3 pH (confirmed by 24-hour pH monitoring) with lansoprazole.

4 negative breath test result while receiving lansoprazole.

5 nsoprazole and 67% of recipients of 30 mg of lansoprazole.

6 azole and 90% of patients receiving 30 mg of lansoprazole.

7 g bolus followed by 9-mg/h infusion) or oral lansoprazole (120-mg bolus followed by 30 mg every 3 hou

8 ontrol 68.3+/-37.8; ranitidine 38.4 +/-94.2; lansoprazole 14.6+/-84.4; and omeprazole 15.1+/-48.9.

9 Lansoprazole, 15 mg or 30 mg, or placebo once daily for

10 ren were randomly assigned to receive either lansoprazole, 15 mg/d if weighing less than 30 kg or 30

11 groups of media: a) control; b) control plus lansoprazole (25 microg/mL); c) control plus omeprazole

12 ith or without a PPI (dexlansoprazole 60 mg, lansoprazole 30 mg, esomeprazole 40 mg, or, as a positiv

13 Lansoprazole, 30 mg twice daily, produced symptom resolu

14 -pyridyl)methylsulfinyl]-1H-ben zimida zole (lansoprazole), 5-difluoromethoxy-2-[3, 4-methoxy-2-pyrid

15 >/=18 years, 50 mg for those <18 years) and lansoprazole (60 mg for participants >/=18 years, 30 mg

16 relatively acid stable analogue, N(1)-methyl lansoprazole, (6b), allowed direct determination of both

17 They were randomly assigned to intravenous lansoprazole (90-mg bolus followed by 9-mg/h infusion) o

18 ceftriaxone (a cephalosporin antibiotic) and lansoprazole (a proton-pump inhibitor) will prolong the

19 whom acid secretion status was monitored on lansoprazole, all were free of significant gastrointesti

20 a dynamic balancing procedure to: 14 days of lansoprazole, amoxicillin, and clarithromycin (standard

21 omization to 1 of 3 treatment groups: 14-day lansoprazole, amoxicillin, and clarithromycin (triple th

22 in, and metronidazole (sequential); or 5-day lansoprazole, amoxicillin, clarithromycin, and metronida

23 clarithromycin (standard therapy); 5 days of lansoprazole, amoxicillin, clarithromycin, and metronida

24 e 50.0% (10.0%-72.0%) for participants given lansoprazole and 5.0% (0.0%-40.0%) for participants give

25 compared with 72% of recipients of 15 mg of lansoprazole and 67% of recipients of 30 mg of lansopraz

26 ared with 79% of patients receiving 15 mg of lansoprazole and 90% of patients receiving 30 mg of lans

27 nidazole (concomitant therapy); or 5 days of lansoprazole and amoxicillin followed by 5 days of lanso

28 , and clarithromycin (triple therapy); 5-day lansoprazole and amoxicillin followed by 5-day lansopraz

29 ive control, we evaluated the combination of lansoprazole and cefuroxime (another cephalosporin), whi

30 ed DNA synthesis in PBMCs when compared with lansoprazole and omeprazole.

31 .05), and no significant difference between lansoprazole and omeprazole.

32 s of many TB drugs, further investigation of lansoprazole as a potential antituberculosis agent is wa

33 Lansoprazole bound to the cysteines in these two domains

34 e is no evidence that, in clinical practice, lansoprazole can treat or prevent incident tuberculosis

35 nsoprazole and amoxicillin followed by 5-day lansoprazole, clarithromycin, and metronidazole (sequent

36 razole and amoxicillin followed by 5 days of lansoprazole, clarithromycin, and metronidazole (sequent

37 s suggested this interaction was specific to lansoprazole combined with ceftriaxone but not with othe

38 improved significantly among patients given lansoprazole compared with placebo.

39 ing inhaled corticosteroids, the addition of lansoprazole, compared with placebo, improved neither sy

40 Complete symptom eradication with lansoprazole does not guarantee normalization of intraes

41 The 15-mg and 30-mg lansoprazole doses did not differ significantly for use

42 The 15-mg and 30-mg lansoprazole doses did not differ significantly in maint

43 Lansoprazole effectively maintains healing of erosive es

44 Prescription of omeprazole, pantoprazole, lansoprazole, esomeprazole, or rabeprazole.

45 Patients enrolled in a long-term trial of lansoprazole for Zollinger-Ellison syndrome and other ac

46 on of hospital stay was 1.8 days in the oral lansoprazole group and 3.9 days in the intravenous esome

47 red with more than 90% of patients in either lansoprazole group.

48 tive metabolite (omeprazole > esomeprazole > lansoprazole > dexlansoprazole) and showed a correspondi

49 patients with a hypersensitivity reaction to lansoprazole had a positive OPT or skin test result with

50 nd that patients taking both ceftriaxone and lansoprazole had significantly longer QTc intervals (up

51 We identified 527,364 lansoprazole initiators and 923,500 omeprazole or pantop

52 Combination therapy of ceftriaxone and lansoprazole is associated with increased risk of acquir

53 clinical trial to investigate the effects of lansoprazole (LANZO) administration, a proton pump inhib

54 The mean difference in change (lansoprazole minus placebo) in the ACQ score was 0.2 uni

55 The suspected PPIs were lansoprazole (n = 52), esomeprazole (n = 11), pantoprazo

56 ffects of Multiple Doses of Dexiansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmaco

57 HODS AND We studied a cohort of new users of lansoprazole, omeprazole, or pantoprazole from the Unite

58 copic therapy were randomly assigned as oral lansoprazole or intravenous esomeprazole group.

59 8 weeks, along with a proton-pump inhibitor (lansoprazole or omeprazole) and bismuth subsalicylate.

60 Similar data were found for lansoprazole or rabeprazole.

61 e minimized by the use of dexlansoprazole or lansoprazole rather than esomeprazole or omeprazole.

62 months, 35% of placebo recipients and 2% of lansoprazole recipients had three or more recurrences.

63 ment with the furazolidone, tetracycline and lansoprazole regimen, twice a day for 7 days.

64 Children treated with lansoprazole reported more respiratory infections (relat

65 rly, esomeprazole but not dexlansoprazole or lansoprazole significantly reduced the effect of clopido

66 st results were positive after completion of lansoprazole therapy were 91% (95% CI, 83% to 96%) at 3

67 s have found the proton pump inhibitor (PPI) lansoprazole to be highly active against Mycobacterium t

68 The other three drugs namely lansoprazole, tolvaptan and roflumilast, were less poten

69 drainage to groups that were given 30 mg of lansoprazole twice daily or placebo.

70 Lansoprazole users had a lower rate of TB disease (n = 8

71 ctice Research Datalink to determine whether lansoprazole users have a lower incidence of TB disease

72 a positive pH study, no treatment effect for lansoprazole vs placebo was observed for any asthma outc

73 There was a significant difference between lansoprazole vs. ranitidine (p< .01), and omeprazole vs.

74 ommonly prescribed and cheaply available PPI lansoprazole was associated with reduced incidence of TB

75 Lansoprazole was significantly superior to placebo in ma

76 After 8 and 16 weeks, participants given lansoprazole were 3.12-fold (1.28-7.59) and 3.50-fold (1

77 y the coadministration of dexlansoprazole or lansoprazole with clopidogrel than by the coadministrati

78 olled, parallel clinical trial that compared lansoprazole with placebo in children with poor asthma c

79 transmission, nor could we determine whether lansoprazole would have a beneficial effect if given to

80 We postulated that sitagliptin and lansoprazole would preserve beta-cell function in patien